恩替卡韦对慢性乙型病毒性肝炎患者HBV DNA、HBsAg及HBeAg定量的影响

发布时间：2019-05-31 17:46

【摘要】：目的观察恩替卡韦对慢性乙型病毒性肝炎(CHB)患者血清乙肝病毒DNA(HBV-DNA)、乙肝表面抗原(HBs Ag)、乙肝e抗原(HBe Ag)定量的影响。方法选取CHB患者160例,均给予恩替卡韦0.5 mg/d空腹口服,持续治疗96周。观察所有患者治疗前、治疗12、24、48及96周后HBV DNA、HBs Ag、HBe Ag定量以及谷氨酸氨基转移酶(ALT)水平,计算HBV DNA、HBe Ag转阴率及ALT复常率,分析HBV DNA变化与HBs Ag、HBe Ag、ALT的相关性。结果随治疗时间延长,患者HBV DNA、HBe Ag定量及ALT水平逐渐降低(F=11.562、28.034、22.417,P0.01);HBe Ag转阴率、HBV DNA转阴率以及ALT复常率逐渐增加;治疗前、治疗12及24周时,HBV DNA与HBs Ag滴度负相关(r=-0.383、-0.293、-0.224,P0.05或P0.01)、与HBe Ag滴度正相关(r=0.441、0.392、0.326,P0.05或P0.01)。结论恩替卡韦治疗CHB疗效确切,可有效促进HBV DNA、HBe Ag转阴率及ALT复常。治疗早期,HBV DNA与HBs Ag负相关、与HBe Ag呈正相关,治疗后期无显著相关性,治疗过程中,应联合多项指标综合评价疗效。
[Abstract]:Objective to observe the effect of entecavir on serum hepatitis B virus DNA (HBV-DNA) and hepatitis B surface antigen (HBs Ag), hepatitis B e antigen (HBe Ag) in patients with chronic viral hepatitis B (CHB). Methods 160 patients with CHB were treated with entecavir 0.5 mg/d for 96 weeks. Before treatment, 24 weeks, 48 weeks and 96 weeks after treatment, the quantity of HBV DNA,HBs Ag,HBe Ag and the level of glutamate aminotransferase (ALT) were observed, the negative conversion rate of HBV DNA,HBe Ag and the recovery rate of ALT were calculated, and the changes of HBV DNA and HBs Ag,HBe Ag, were analyzed. The correlation of ALT. Results with the prolongation of treatment time, the quantity of HBV DNA,HBe Ag and the level of ALT decreased gradually (F 鈮，

本文编号：2489900